Bringing an Over-the-Counter (OTC) drug to market is a high-stakes endeavor. If you missed our live webinar about Launching an OTC Product the Right Way, here are the three most critical takeaways that every brand owner needs to know and how to avoid the most common pitfalls that delay launches and trigger FDA enforcement.
Outsourcing Does Not Absolve You of Liability
The “Virtual Company” Myth
There is a dangerous misconception in the industry that if you are a “virtual company”, meaning you outsource your manufacturing, packaging, and testing, you are immune to GMP (Good Manufacturing Practice) inspections.
The Reality
The owner or distributor of the drug product is ultimately responsible for every aspect of compliance. You cannot contract away your regulatory liability. If your contract manufacturer (CMO) or testing lab cuts corners, you are liable.
Actionable Advice
- Conduct Due Diligence: Don’t just trust; verify. You must audit your suppliers and labs to ensure they are GMP-compliant and FDA-registered.
- Own Your Data: Do not leave critical documents solely in the hands of your partners. You must obtain and keep copies of batch manufacturing records, stability reports, process validation reports, and annual product reviews in your own files. If the FDA knocks on your door, saying “my manufacturer has those” is not an acceptable answer.
Accelerated Stability is an Approximation, Not a Guarantee
Everyone wants to launch fast. To do this, companies typically rely on accelerated stability testing, which involves storing the product at 40°C/75% RH to predict how a product will hold up over time. While the FDA allows you to launch based on this data, often accepting 3 to 6 months of accelerated results to justify a tentative 2-year expiration date, it is technically just an extrapolation.
The Risk:
What happens if your product degrades faster than predicted? For example, soft gels often fail under accelerated heat conditions even if they are stable at room temperature.
Actionable Advice
- Start Real-Time (RT) Stability Immediately: Initiate RT testing (25°C/60% RH) concurrently with your accelerated testing. This data is the only way to “prove” your accelerated prediction was correct.
- Consider Intermediate Testing: To protect yourself against unexpected failures at high temperatures, run an “intermediate” stability study (30°C/65% RH) as a backup. This can provide a safety net that saves your product launch if the accelerated samples fail.
Strategic Sequencing Can Cut Launch Time to 4 Months
Many launches drag on for a year or more due to poor planning. The 10-step process outlined in the webinar and our blog is designed to streamline development. The key is performing tasks in a logical order so you don’t have to backtrack.
For example, you must finalize your formulation and primary packaging (Step 2) before you can start stability testing (Step 5). If you change your plastic bottle halfway through, your stability data will be invalid, and you will have to start over.
The Payoff
- Speed: With a solid team and strict adherence to this logical sequence, It is possible to bring a compliant OTC product to market in as little as four months.
- Cost: Proper planning prevents wasted resources on formulas that don’t meet the monograph or packaging that fails compatibility testing.
Need a Partner for Your OTC Drug Product Launch?
Whether you need help validating a method, auditing a supplier, or planning your stability protocols, CPT Labs offers consulting and testing services to ensure your product is compliant from launch.